Middle segment pancreatectomy in treatment for pancreatic neck and body tumors: clinical analysis of 26 cases

Abstract

Objective To investigate the clinical efficacy of middle segment pancreatectomy (MSP) in treatment for pancreatic neck and body tumors. Methods From Jan. 2000 to Dec. 2016, the clinicopathological data of 26 patients with pancreatic neck or body tumors were analyzed retrospectively. Results All of the 26 patients received middle segment pancreatectomy. 14 cases had serous or mucinous cystadenomas. The tumor diameter was 2.3 to 5.6 cm (averaging from 3.8 cm) . 9 cases had solid pseudopapillary tumors. The tumor diameter was 3.3 to 5.0 cm (averaging from 3.6 cm) ; One case had insulinoma and the diameter was 2.0 cm. Two cases had nonfunctional pancreatic neuroendocrine tumors, and the diameter was 2.1 and 2.4 cm. The post-complication morbidity rate was 53.8%. The main post-complications of the group were pancreatic fistula (9 cases,34.2%) , intra-abdominal infection (1 case, 3.8%) , delayed gastric emptying (2 cases, 7.6%) , lymphatic fistula (1 case, 3.8%) , and abdominal infection (1 case, 3.8%) . All of the 26 patients healed after surgery without undergoing surgery again. There were no mortality during perioperative period. All patients were followed up for 6 to 60 months. All of the 26 patients had good life quality, without new-onset diabetes or cancer recurrence during the follow-up period of 6 to 60 months after operation. Conclusion Middle segment pancreatectomy is safe and feasible in treatment of benign or low-graded malignant pancreatic neck and body tumors and is capable of preserving pancreatic endocrine and exocrine function. Key words: Pancreatic tumors; Middle segment pancreatectomy; Complication